Your coder pulls up a pathology report with a borderline finding and has to choose between six columns in the Neoplasm Table before the claim goes anywhere. That choice has real money attached to it. Pick the wrong behavior column, and the payer sends it back weeks later. A March 2024 MGMA Stat poll found that 60% of medical group leaders reported an increase in claim denial rates compared to the prior year, and neoplasm chapter coding errors are a regular part of that trend. Getting neoplasm ICD 10 codes right isn't abstract compliance work. It shapes how quickly your practice collects.
A neoplasm is an abnormal tissue growth. Some are cancerous, most aren't, and that single distinction controls every coding decision that follows.
ICD-10-CM Chapter 2 (C00 through D49) sorts neoplasms by site and behavior. An icd 10 malignant neoplasm sits in the C00 through C96 range for primary sites, with benign, uncertain, and unspecified in their own blocks.
| Behavior category | ICD-10 range | When to use |
| Malignant (primary) | C00 through C96 | Confirmed malignancy at the originating site |
| Malignant (secondary) | C77 through C79 | Cancer that has spread to another site |
| Carcinoma in situ | D00 through D09 | Malignant cells haven't invaded surrounding tissue |
| Benign | D10 through D36 | Non-cancerous growths confirmed by pathology |
| Uncertain behavior | D37 through D48 | A pathologist can't call it malignant or benign |
| Unspecified behavior | D49 | The record doesn't say what type it is |
One thing coders frequently skip: checking the Alphabetic Index before going to the Neoplasm Table. If a histological term shows up in the documentation, that term gets looked up first. The Table comes second, the Tabular List confirms the code with any Excludes notes, and bypassing that sequence is where many ICD-10 mistakes that trigger rejections start.
Four anatomical sites dominate oncology claim volume, and each trips up billing teams differently.
Malignant neoplasm of breast. Codes C50.011 through C50.929 break down by quadrant, laterality, and overlapping boundaries. Laterality has to be documented every time, and coders who skip it end up reworking claims.
Malignant neoplasm of prostate ICD 10. C61 covers primary prostate malignancy with no subcategories. Simple on paper, but practices routinely keep reporting C61 after definitive treatment when Z85.46 should have replaced it.
Malignant neoplasm of skin. C43 handles melanoma, C44 covers non-melanoma types. Both demand an anatomical site, and a note that just says "skin cancer" gives your coder nothing specific to assign.
Brain neoplasm ICD 10. C71.0 through C71.9 cover primary tumors by location, while C79.31 and C79.32 handle secondary ones. Whether the tumor started in the brain or arrived from somewhere else changes the code completely.
When coding malignant neoplasm of skin ICD 10 categories, the pathology report needs to specify melanoma versus squamous or basal cell carcinoma, as these fall in different code families.
For neoplasm of brain ICD 10 entries, practices with steady oncology billing volume should build encounter templates that prompt for tumor location and primary versus metastatic status.
This is where the most preventable denials in the Neoplasm Table happen.
A neoplasm of uncertain behavior (D37 through D48) means a pathologist looked at the tissue and couldn't call it malignant or benign. That finding comes from the pathology report, not from clinical suspicion.
Codes for ICD 10 neoplasm of uncertain behavior get confused with unspecified behavior (D49) constantly. Unspecified means the record lacks enough detail. It's a documentation gap, not a pathology finding.
Assigning a neoplasm of uncertain behavior ICD 10 code without pathology confirmation puts the claim at risk during any audit. Rules here shift depending on the payer, so checking payer-specific policies is worth the time if your practice bills these regularly.
When looking up the ICD 10 code for neoplasm of uncertain behavior, verify the site against the Tabular List. Codes under D37 through D48 carry different Excludes notes. Tracking denial patterns through your denial management process prevents the same errors from cycling through your medical group billing workflow month after month.
Two areas most neoplasm guides skip, but both come up on gastroenterology and oncology claims regularly.
Intraductal papillary mucinous neoplasm ICD 10 coding hinges on whether the IPMN is benign, malignant, or uncertain. Without dysplasia, it usually falls under D13.6. A malignant IPMN goes to C25. Providers sometimes document "pancreatic cyst" and leave it there, which gives the coder almost nothing to work with.
For neoplasm pain ICD 10 situations, G89.3 goes first when the visit is primarily about managing pain. If the encounter targets the neoplasm itself, the neoplasm code leads, and G89.3 drops to additional. Sequencing here directly affects what your practice collects, so your medical coding team has to confirm the visit purpose before assigning the order.
The wrong behavior category tops the list. Assigning uncertain behavior without pathology backup, or defaulting to unspecified when documentation supports something more specific, hands the payer a reason to deny.
Missing site documentation is a different problem because it starts with the provider. "Skin lesion" with no anatomical location means no site-specific code. That's a clean claim failure that originates in the exam room.
A pre-submission claim scrubbing process catches a lot of this before it reaches the payer. And something most practices underuse: a feedback loop between coders and providers. Practices that run regular audits and close that gap consistently outperform those that fix things after the denial arrives. Most revenue cycle management frameworks list it as a baseline recommendation.
Accurate neoplasm ICD 10 coding goes beyond looking up a code. It requires provider documentation that specifies site and behavior, proper use of the Alphabetic Index before the Neoplasm Table, and coders who know what separates uncertain from unspecified. Wrong column, missing site detail, no pathology support: those three errors account for most Chapter 2 denials, and every one is fixable.
Start with an audit of uncertain and unspecified behavior assignments if you're seeing a pattern. RCM Matter can help pinpoint where those breakdowns start and build a coding workflow that stops them from repeating.
What is the ICD-10 code for neoplasm?
No single code covers it. Neoplasm codes run from C00 through D49, organized by site and behavior. You need pathology findings and documented tumor location to land on the right one.
What is the ICD-10 code for malignant neoplasm?
C00 through C96 by body site for primary malignancies, while C79 handles metastatic sites. For outpatient encounters, clinical suspicion alone doesn't support a malignant code.
What is the ICD-10 code for neoplasm of uncertain behavior?
D37 through D48. Only use these when a pathologist states the behavior can't be determined. Don't fall back on D48.9 because the documentation is incomplete. That's a provider query situation, not a coding shortcut.
What is the ICD-10 code for malignant neoplasm of the prostate?
C61. Straightforward code, but the mistake practices make is continuing to use it after treatment wraps up and no active disease remains. Z85.46 should take over at that point.
What is the difference between uncertain and unspecified behavior?
Uncertain means a pathologist examined the tissue and couldn't classify it either way. Unspecified means nobody documented the behavior type at all. One comes from clinical analysis, the other from a gap in the record, and payers adjudicate them very differently.
Optimize billing, claims and collections with expert RCM support let our professionals handle the process so you can focus on patient care.
